The recent spread of the novel coronavirus, SARS-CoV-2 has created a worldwide public health emergency. In December 2019, the outbreak of this emerging disease (COVID-19) began in Wuhan, China. It quickly spread, and a pandemic was declared by the World Health Organization in March 2020 [@bib0001],[@bib0002].

Repositioning drugs already approved for use in humans is a useful tool to search for new therapeutic options, particularly in the current global crisis [@bib0003]. Thus, drug repositioning, also known as redirecting, repurposing, and reprofiling [@bib0004],[@bib0005], emerges as an effective possibility for generating new treatments against COVID-19. Repositioning is defined as a new use of a drug, in addition to its original indication(s), and is an option for rapid identification of new therapeutic agents. The availability of drug-related information, such as pharmacokinetics, pharmacodynamics and toxicity [@bib0006], is an important advantage in the research efforts to quickly find an effective treatment for this deadly virus.

[Table 1](#tbl0001){ref-type="table"} presents a selection of recent studies that investigated the antiviral activity of several pharmacological classes, including antimalarial drugs and antibiotics, as options for repositioning as treatments of coronavirus (SARS-CoV, SARS-CoV-2 and HCoV-OC43) [@bib0007], [@bib0008], [@bib0009], [@bib0010]. A search was conducted on three databases (PubMed, SCOPUS and Web of Science) between March 15 th and March 27 th, 2020 using the following search strategy: \[(repositioning) AND (repurposing) AND (redirecting) AND (reprofiling) AND (rediscovery) AND (COVID-19) AND (CORONAVIRUS) AND (treatment)\] with review filters appropriate for individual databases. The inclusion criterion was studies that included the repositioning of drugs with antiviral activity against coronavirus. Duplicate cases were excluded, as were studies that did not address the issue.Table 1Studies of the repositioning of drugs with effects against coronavirus.Table 1DrugClassOriginal indicationNew indication in repositioningType of studyActive concentrationProbable mechanism of actionReferenceAmodiaquine4-amino-quinolineAntiparasitic agentSARS-CoVIn vitroEC~50~ = 1.274-Dyall et al. 2014 [@bib0013]CaptoprilACE-2 inhibitorHypertensionSARS-COV-2Hypo-thesis-Inhibits binding between COVID-19 and human ACE-2, and reduces symptoms of severe pneumoniaSun et al. 2020 [@bib0014]Chloroquine4-amino-quinolineAntimalarialSARS-CoVIn vitroEC~50~ = 6.538-Dyall et al., 2014 [@bib0013]SARS-CoVIn vitroIC~50~ = 8.8 µM-Keyaerts et al., 2004 [@bib0015]SARS-CoVIn vitroEC~50~ = 4.1 µM\
CC~50~ ≥ 128 µM-de Wilde et al., 2014 [@bib0016]SARS-CoV-2In vitroEC~50~ = 1.13 µMProbably blocks virus infection by increasing endosomal pH required for virus/cell fusion, and interferes with glycosylation of cellular receptors of SARS-CoVWang et al., 2020 [@bib0007]SARS-CoV-2In vitroEC~50~ = 2.71 µMBlocks virus transport between cell organellesLiu et al., 2020 [@bib0009]SARS-CoV-2In vitroEC~50~ = 5.47 µMYao et al., 2020 [@bib0017]SARS-CoV-2Comput-ational\--Gordon et al., 2020 [@bib0018]SARS-CoV-2In vivo\--Gao et al,, 2020 [@bib0008]HCoV-OC43In vivoEC~50~ = 0.3 µMProbably affects endosome-mediated fusionKeyaerts et al., 2009 [@bib0019]Cyclosporin ACalcineurin inhibitorsImmuno-supressantSARS-CoVIn vitro16 µMLikely that the drug interferes with functional interactions between viral proteins and one or multiple members of the large cyclophilin familyde Wilde et al., 2011 [@bib0020]SARS-CoVIn vitroEC~50~ = 3.3 µMAffects replicative proteinPfefferle et al., 2011 [@bib0021]Chlorpromazine hydrochlorideAntipsychoticSchizophreniaSARS-CoVIn vitroEC~50~ = 8.8 µM\
CC~50~ = 24.3 µM-de Wilde et al., 2014 [@bib0016]ClomipramineNeurotransmitter inhibitorAntidepressantSARS-CoVIn vitroEC~50~ = 13.2 µM-Dyall et al., 2014 [@bib0013]DisulfiramTiuram dissulphideChronic alcohol dependenceSARS-CoVIn vitroIC~50~ = 24.1 µMCompetitive inhibitor of SARS-CoV papain-like proteaseLin et al, 2018 [@bib0022]EnalaprilACE-2 inhibitorHypertensionSARS-COV-2Hypo-thesis-Inhibits binding between COVID-19 and human ACE-2, and reduces symptoms of severe pneumoniaSun et al., 2020 [@bib0014]Gemcitabine hydrochlorideDNA metabolism inhibitorAnticancerSARS-CoVIn vitroEC~50~ = 4.9 µM-Dyall et al., 2014 [@bib0013]Hydroxychloroquine4-amino-quinolineAntimalarialSARS-CoVIn vitroEC~50~ = 7.9 µM-Dyall et al., 2014 [@bib0013]SARS-CoV-2In vivo0.46 µg/mL (serum concentration)-Gautret et al., 2020 [@bib0011]SARS-CoV-2In vitroEC~50~ = 2.71 µMBlocks virus transport between cell organellesLiu et al., 2020 [@bib0009]SARS-CoV-2In vitroEC~50~ = 0.72 µM-Yao et al., 2020 [@bib0017]DasatinibKinase signaling inhibitorAnticancerSARS-CoVIn vitroEC~50~ = 2.1 µM-Dyall et al., 2014 [@bib0013]Imatinib mesylateKinase signaling inhibitorAnticancerSARS-CoVIn vitroEC~50~ = 9.8 µM-Dyall et al., 2014 [@bib0013]LoperamideOpioidAntidiarrhealSARS-CoVIn vitroEC~50~ = 5.9 µM\
CC~50~ = 53.8 µM-de Wilde et al., 2014 [@bib0016]MefloquineAminoquinolineAntiparasitic agentSARS-CoVIn vitroEC~50~ = 15,5 µM-Dyall et al., 2014 [@bib0013]MetforminBiguanideDiabetesSARS-CoV-2Comput-ational\--Gordon et al., 2020 [@bib0018]NitazoxanideNitrothiazoleAntimalarialSARS-CoV-2In vitroEC~50~ = 2.12 µM-Wang et al., 2020 [@bib0007]Promethazine hydrochlorideNeurotransmitter inhibitorAntihistamineSARS-CoVIn vitroEC~50~ = 7.5 µM-de Wilde et al., 2014 [@bib0016]RemdesivirNucleoside analogClinical development for treatment of Ebola virus infectionSARS-CoV-2In vitroEC~50~ = 0,77 µM; IC ~50~  \> 100 µMAdenosine analogue incorporates into nascent viral RNA chains and results in premature terminationWang et al., 2020 [@bib0007]TamoxifenEstrogen receptor inhibitorBreast cancerSARS-CoVIn vitroEC~50~ = 92.8 µM-Dyall et al., 2014 [@bib0013]TerconazoleSterol metabolism inhibitorAntifungalSARS-CoVIn vitroEC~50~ = 92.8 µM-Dyall et al., 2014 [@bib0013]ToremifeneEstrogen receptor inhibitorBreast cancerSARS-CoVIn vitroEC~50~ = 11.9 µM-Dyall et al., 2014 [@bib0013]TeicoplaninGlycopeptide antibioticBacterial infectionSARS-CoV-2In vitroIC~50~ = 1.66 µMInhibited entry of 2019-nCoV pseudovirus, which provides a possible strategy for prophylaxis and treatment for 2019-nCoV infectionZhang et al., 2019 [@bib0010][^1]

The analysis revealed seven studies that address drug repositioning against SARS-CoV-2; the target drugs were chloroquine, hydroxychloroquine associated with azithromycin, teicoplanin, remdesivir, nitazoxanide and metformin. Several authors report the potential of chloroquine as a therapeutic option against this virus: in vitro it presented an EC~50~ of 1.13 µm and in vivo it caused a negative conversion of the virus in more than 100 patients who were participating in multicenter clinical trials conducted in China [@bib0007],[@bib0008]. In the in vitro study performed by Liu et al. (2020), both chloroquine and hydroxychloroquine inhibited the virus from entering the cell and, at later cell stages of SARS-CoV-2 infection, blocked virus transport between cell organelles, which is considered a determining step for the release of viral genome in cells in the case of SARS-CoV-2. However, chloroquine was observed to have a higher efficacy [@bib0009].

Teicoplanin, on the other hand, presented an in vitro IC~50~ of 1.66 µM, a relatively low active concentration, which is promising for its use against SARS-CoV-2; however, this requires further in vivo verification and incorporation in clinical trials [@bib0010].

Gautret et al. (2020) conducted a clinical trial using hydroxychloroquine in patients infected with SARS-CoV-2. The initial results show a significant reduction in viral carriage and the use of hydroxychloroquine in conjunction with azithromycin was more efficient in eliminating the virus [@bib0011]. There is also expectation for the results of the WHO solidarity initiative, which consisted of a worldwide call for a clinical study to simultaneously research the efficacy of four drugs, including remdesivir, chloroquine and hydroxychloroquine, for the treatment of patients affected with COVID-19 [@bib0012]. Thus, drug repositioning is a promising alternative for the treatment of COVID-19 disease, and a more complex investigation of the antiviral effect of these molecules against SARS-CoV-2 is encouraged.
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[^1]: (-) Not determined
